The risk of cancer in users of statins
The risk of cancer in users of statins
复制标题
DOI：
10.1200/jco.2004.02.027
复制
发表时间：
2004-06-15
影响因子：
45.3
通讯作者：
Guchelaar, HJ
中科院分区：
文献类型：
--
作者：
Graaf, MR;Beiderbeck, AB;Guchelaar, HJ
目的：一些临床前研究表明3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂（他汀类）在癌症治疗中的作用。本研究的目的是比较他汀类药物的用户和其他心血管药物的用户之间的癌症事件的风险。MethodsData从PHARMO数据库，包含从社区药房的药物分配记录和8个荷兰城市的居民的医院出院记录。研究基础包括在1985年1月1日至1998年12月31日期间有一个或多个心血管药物处方的所有患者。病例被确定为研究基地中诊断为偶发癌症的患者，并与4至6名对照组在性别、出生年份、地理区域、随访持续时间和索引日期上相匹配。分析调整糖尿病，以前的住院，合并症;和使用利尿剂，血管紧张素转换酶抑制剂，钙通道阻滞剂，非甾体抗炎药，性激素，和其他降脂药物therapy.ResultsIn研究基地，3,129例患者被确定和匹配的16,976对照。他汀类药物的使用与癌症风险降低20%相关（校正比值比（OR），0.80; 95%CI，0.66至0.96）。我们的数据表明，他汀类药物是保护时，使用时间超过4年（调整OR，0.64; 95%CI，0.44至0.93）或超过1,350定义的每日剂量时，采取（调整OR，0.60; 95%CI，0.40至0.91）。(C)2004年，美国临床肿瘤学会。
PurposeSeveral preclinical studies suggested a role for 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) in the treatment of cancer. The objective of this study was to compare the risk of incident cancer between users of statins and users of other cardiovascular medication.MethodsData were used from the PHARMO database, containing drug dispensing records from community pharmacies and linked hospital discharge records for residents of eight Dutch cities. The study base included all patients with one or more prescriptions for cardiovascular drugs in the period between January 1, 1985 and December 31, 1998. Cases were identified as patients in the study base with a diagnosis of incident cancer and matched with four to six controls on sex, year of birth, geographic region, duration of follow-up, and index date. The analysis was adjusted for diabetes mellitus, prior hospitalizations, comorbidity; and use of diuretics, angiotensin-converting enzyme inhibitors, calcium-channel blockers, nonsteroical anti-infiammatory drugs, sex hormones, and other lipid-lowering drug therapies.ResultsIn the study base, 3,129 patients were identified and matched to 16,976 controls. Statin use was associated with a risk reduction of cancer of 20% (adjusted odds ratio (OR], 0.80; 95% CI, 0.66 to 0.96). Our data suggest that statins are protective when used longer than 4 years (adjusted OR, 0.64; 95% CI, 0.44 to 0.93) or when more than 1,350 defined daily doses are taken (adjusted OR, 0.60; 95% CI, 0.40 to 0.91).ConclusionThis observational study suggests that statins may have a protective effect against cancer.(C) 2004 by American Society of Clinical Oncology.